Diabetic Gastroparesis adversely affects 20-40% of longstanding type 1 diabetics and may worsen blood glucose control, but our diabetic patients may not have any other symptoms! Discover the effects of high and low sugar on the normal and neuropathic gut, and learn what you can do help manage this difficult disorder.
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
Diabetic gastroparesisv2011
1. Diagnosing & Managing
Diabetic Gastroparesis
Patricia L. Raymond MD FACP FACG
• Assistant Professor of Clinical Internal
Medicine, Eastern Virginia Medical
School
• Gastroenterology Consultants, a
division of Gastrointestinal & Liver
Specialists of Tidewater pllc
3. GI tract among many organ systems affected
by diabetic autonomic neuropathy
• Cardiovascular
• Genitourinary
• Neuroendocrine
• Gastrointestinal tract
• Upper
• Lower
4. How frequent are gastrointestinal
symptoms in diabetics?
• 1101 subjects from outpatient
clinics and the community
• GI symptoms associated with
autonomic or peripheral
neuropathy (OR 1.62-2.39)
• Constipation 29%
• GERD 19%
• Dyspepsia 14%
• Abdominal pain 11%
• Fecal incontinence 9%
Bytzer, P. Am J Gastroenterol 2002; 97:604.
5. ACG 2011 Abstract #468:
Economic Burden of Diabetic
Gastroparesis
• 3498 hospitalizations in 2006
• $2293 per hospitalization
• $76 million annually
6. Esophageal involvement
• GERD from autonomic neuropathy
with decreased LES pressure,
impaired peristaltic clearance of
esophagus, delayed gastric
emptying
• Normals with hypergycemia (15
mm/l, 8 mm/l) with impaired transit
and elevated TLESRs compared
with euglycemia
Rayner, CK. Diabetes Care 2001; 24:371.
8. Diabetic Gastroparesis
• True prevalence unclear
• 20-40% of diabetics, especially long
standing type I
• Magnitude of delay does not
correlate with symptoms
• Lack symptoms from neuropathy
afferent sensory nerve fibers
• Hyper-reactive symptoms
• Results in poor glycemic control
9.
10.
11. Blood glucose affects gastric
contractions
• Normal, non
diabetic
subjects
• Gastric
contractions
nearly absent at
250 mg/dl
• Markedly
reduced at 140
and 175 mg/dl
Barnett, JL. Gastroenterology 1988; 94:739.
12. Fast = Goes fast!
• Hypoglycemia
leads to
accelerated
gastric
emptying even
in patients with
delay in gastric
emptying
Russo, A. J Clin Endocrinol Metab 2005; 90:4489.
13.
14. Just too sensitive?
• Increased sensitivity with elevated
blood glucose within physiologic
range
• Esophagus
• Threshold for perception of balloon
distension lowered
• Stomach
• Nausea, fullness, epigastric pain
Rayner, CK. Diabetes Care 2001; 24:371.
Parkman, HP. Gastroenterology 2004; 127:1592.
15.
16. Diagnosis of Gastroparesis
• EGD
• Scintigraphy
• Solid
• Liquid
• Both
• Rare testing
• EGG (Electrogastrogram), MRI,
US, Isotope breath testing
• (only done at some motility centers)
25. Watch out!
• Poor correlation between
magnitude of delay and symptoms
• No data to support improving
assymptomatic gastroparesis
• improves long term diabetes control
or prevents diabetes complications
• Treat for symptom relief
Stacher, G. J Clin Endocrinol Metab 1999; 84:2357.
26. Treatment of Gastroparesis
• Dietary maneuvers
• Low residue
• aka the Twinkie ® diet
• Take a hike
• Medications
• Endoscopic treatment/Botox
• Gastric pacemaker
• Feeding tube
27.
28. Low residue diet
You should avoid:
• Whole-grain
breads, cereals
and pasta
• Whole vegetables
and vegetable
sauces
• Whole fruits,
including canned
fruits
• Seeds and nuts
29.
30. Take a hike
• Postprandial walking
• 50 patients with DM
• Emptying rates of 28
patients (56%) were
within normal range of
controls
• 4 patients with
accelerated emptying
(8%).
• 18 patients with delayed
emptying (36%)
Lipp, R. W. American Journal
of Gastroenterology 2000; 95(2), 419–424.
31. Postprandial walking
• Two variants of delayed gastric emptying
(18 of 50 patients):
• Counteracted by postprandial walking in 7
patients (39% of GP)
• Not influenced
by postprandial
walking in 11
patients (61% of GP)
34. Erythromycin
• Erythromycin
• 3mg/kg IV over 45 min to ‘kick-start’
stomach
• High amplitude gastric propulsive
contractions which dump solid residue out
of stomach
• Evidence for po Erythro weak
• 35 trials, only 5 ‘fulfilled inclusion criteria’,
all small #,all short (< 4 weeks)
• Improvement in 26 of 60 patients (43%)
Prather, CM. Am J Physiol 1993; 264:G928.
Keshavarzian, A. Am J Gastroenterol 1993; 88:193.
Maganti, K. Am J Gastroenterol 2003; 98:259.
35. Erythromycin potential side
effects
• GI toxicity
• Ototoxicity
• Pseudomembranous colitis
• Resistant bacterial strains
• Sudden death due to
prolonged QT interval
36. ACG 2011 Abstract # 875:
Azithromycin verses Erythromycin
• 13 patients, • AZI may be
crossover trial better due to
• 100 mg AZI • longer half life
• Breath-testing • better SE
profile
prior to
• lack P450
crossover
interaction
• Findings:
Bioequivalent
37. 1-800-SoSueMe: Reglan
• PO or SQ
• Tardive dyskinesia
• Irritability, anxiety,
depression, hyperprolactinemia
• 2010 meta analysis UK &
Sweden tardive dyskinesia
<1%, may be reversible if
caught early
Rao, AS. Aliment Pharmacol Ther 2010; 31:11.
38. Reglan/Metaclopramide po:
Start low, give holidays
• 5mg 15 minutes • Notify MD for
AC and HS any involuntary
• Titrate upward movement
(to 40 mg/day) • Early
• Consider liquid recognition and
version, SQ drug
• Drug holidays discontinuation
or occasional may lead to
dose reductions resolution
39. Cisapride and Zelnorm:
Can’t Get No Satisfaction
• Cisapride: QT interval
issues with cardiac
arrhythmias and death
• 5HT3 receptor agonist
• Increased solid and liquid
emptying in various gastric
stasis conditions
• More potent and better
tolerated than reglan
• Zelnorm: Yanked by FDA
40. Oh Canada! Domperidone
• Not FDA approved for
use in the US
• Can be obtained through
IND application
• May be compounded by
local pharmacists or
purchased overseas by
internet
• Efficacy similar to
metaclopramide
• Cardiac arrhythmias in
animal studies
41. ACG 2011 Abstract #878:
Domperidone at Walter Reed
• 13 patients
• 54% improved on
domperidone
• Dosage 20 to 80
mg daily (median
40 mg daily)
• No QT changes,
no SE, no lab
abnormalities
42.
43. Antiemetics
• Antihistamine
• Diphenhydramine (Benadryl)
• Oral or rectal
• Phenothiazines
• Compazine
• IV or rectal
• HT3 Antagonists
• Ondansetron (Zofan), granisitron
(Kytril) no advantage over
conventional agents
44. Endoscopy with botox
• Pilot studies
injecting botox
into pylorus
helped gastric
emptying
45. Rethinking botox
• Controlled trial 32 patients
• No difference in emptying or symptoms
compared with placebo at 1 month
• Crossover trial 23 patients
• No improvement symptoms or rate of
gastric emptying
• “Larger, controlled trials are needed”
Friedenberg, FK. Am J Gastroenterol 2008; 103:416.
Arts, J. Aliment Pharmacol Ther 2007; 26:1251.
46. Abstract #467 ACG 2011:
Botox or Pyloric Balloon with
Normal 3 cpm EGG
• 18 patients with • 15 improved after
normal EGG slow 2 interventions, 3
GES, normal EGD no response
• 4 quadrant botox • Symptom free for
100 mcg or 20 mm 4 months average
balloon x 2 • Retreatment at
minutes relapse
• If no symptom
improvement,
other intervention
done
49. The lure of gastric pacemakers
• Photo gastric • Better
pacemaker symptoms, but
no improvement
in emptying
• Limited efficacy,
humanitarian
use device
Abell, T. Gastroenterology 2003; 125:421.
McCallum, R. Gastroenterology 2009; AB376.
50. ACG 2011 Abstract #877:
Mucosal Nerve Fiber Density
• 5 GP patients (1 • MNF density
DM, 2 idiopathic, 2 reduced in
post-op), 3 age GP.0018 vs .0024
matched controls (p=.02)
• GP patients had • MNF density
full thickness correlates with
biopsies at pacer symptom severity
implant • MNF density
correlates with
duration of
disease
55. Gastroparesis
• Symptoms don’t correlate with
degree of emptying impairment
• EGD and scintigraphy to diagnose
• Lifestyle changes as mainstay of
treatment
• Reglan not as evil as previously
supposed, newer management
continues to be a ‘wash out’